GlassScriptPhysician profile
Robert M Rose
NPI 1396717450
$2,050.49
in general payments reported to CMS, 2019-2025
25 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $67.15 · 2022: $196 · 2023: $864 · 2024: $285 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $282.76 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $210.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $176.92 | 2022-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $170.12 | 2019 | |
| Amgen INC. | $154.33 | 2022-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $152.82 | 2023-2024 | Amvuttra |
| Edwards Lifesciences Corporation | $120.83 | 2022-2023 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $106.66 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.06 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $66.22 | 2019-2020 | |
| Abbott Laboratories | $60.75 | 2023-2025 | Aveir, Gallant |
| Astrazeneca Pharmaceuticals LP | $55.89 | 2023-2024 | Farxiga |
| Gilead Sciences, INC. | $49.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $44.53 | 2019 | |
| Lilly USA, LLC | $42.95 | 2023-2025 | Mounjaro, Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $41.62 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $40.86 | 2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $39.53 | 2023 | Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $29.49 | 2023 | Arcalyst |
| Boston Scientific Corporation | $28.16 | 2019 | |
| Novo Nordisk INC | $24.83 | 2024 | Wegovy |
| Bardy Diagnostics, INC. | $20.64 | 2020 | |
| Exact Sciences Corporation | $20.61 | 2023 | Cologuard Collection Kit |
| Scpharmaceuticals INC. | $18.98 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.